Diagnostic and predictive tool D2HGlo for glioma patients
Official title: Validation of the Diagnostic and Predictive Tool, D2HGlo, for the Quantification of the Oncometabolite D-2-Hydroxyglutarate (D-2-HG) in Glioma
Funded at Northern Michigan University · NIH-11418321 · Data updated 2026-11-12
A new liquid biomarker test (D2HGlo) aims to help people with IDH-mutant gliomas by measuring D-2-HG levels to guide treatment decisions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern Michigan University NIH-funded |
| Lab location | 1 site (Marquette, United States) |
| Project start | September 18, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $103,412 |
| NIH project number | 5UH3CA297234-02 |
| Project ID | NIH-11418321 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with mutant IDH glioma who may benefit from non-invasive biomarker testing to inform treatment decisions.
✕Less likely to help
Patients without IDH-mutant glioma or those not undergoing diagnostic/prognostic biomarker testing may not benefit.
What this research studies
This project partners NMU, JHU, and Kennedy Krieger to analytically and clinically validate a liquid, genetically encoded probe called D2HGlo. The test detects the oncometabolite D-2-HG in non-invasive samples, potentially offering earlier insight into how a patient’s glioma may respond to therapy. If successful, D2HGlo could complement MRI by predicting treatment response months sooner and help tailor management for individuals with IDH-mutant glioma.
Why it matters
Potential benefit: If successful, the test could lead to earlier, more personalized treatment choices for glioma patients based on their tumor biology.
How similar studies have gone: Preliminary work with liquid biomarkers in glioma shows promise, and this project builds on established concepts with a novel, non-invasive assay.
Where this research is happening
-
Northern Michigan University
Marquette, United States Active
Researchers
- Principal investigator: Jennings, Matthew James — Northern Michigan University
- Study coordinator: Jennings, Matthew James
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.